PO-1536 Using weekly digital patient-reported outcomes to evaluate toxicity for patients at the MR-linac von Moeller, P.K., Bernchou, U., Schytte, T., Pappot, H., Bertelsen, A.S., Dysager, L., Nyborg, C.J, Dieperink, K.B.

Volltext

OC-0711: Acute toxicity of MR-guided radiotherapy for prostate cancer at the 1.5 T MR-linac von Møller, P.K., Gornitzka, J., Bernchou, U., Dysager, L., Bertelsen, A.S., Nyborg, C.J., Schytte, T.

Volltext

OC-0136 Acute toxicity reported by patients with prostate cancer receiving online MR-guided radiotherapy von Møller, P.K., Dysager, L., Bernchou, U., Bertelsen, A.S., Brink, C., Mahmood, F., Jensen, H.R., Hansen, O., Nyborg, C.J., Pappot, H., Dieperink, K.B.

Volltext

PO-1689 Potential NTCP reductions for high-risk prostate cancer patients by MR-guided adaptive radiotherapy von Christiansen, R.L., Dysager, L., Hansen, C.R., Schytte, T., Bertelsen, A.S., Jensen, H.R., Mahmood, F., Nyborg, C.J., Hansen, S., Agergaard, S.N., Hansen, O., Brink, C., Bernchou, U.

Volltext

PO-1421 Is it possible to deliver on-line MR-guided RT for prostate cancer within a feasible time frame? von Schytte, T., Møller, P.K., Bernchou, U., Gottlieb, K.L., Lorenzen, E.L., Agergaard, S., Jensen, H.R., Nyborg, C.J., Dysager, L., Hansen, O., Mahmood, F., Bahij, R., Brink, C., Bertelsen, A.S.

Volltext

MO-0879 Automatic detection of delineation outliers at an MR linac von Brink, C., Bernchou, U., Hazell, I., Bertelsen, A., Lorenzen, E.L., Hansen, C.R., Christiansen, R.L., Sarup, N., Agergaard, S.N., Gottlieb, K.L., Jensen, H.R., Bahij, R., Dysager, L., Nyborg, C.J., Hansen, O., Schytte, T.

Volltext

PD-0571 Determining interobserver variability in prostate bed CTV target delineation using MRI von Sritharan, K., Akhiat, H., Cahill, D., Choi, S.L., Choudhury, A., Chung, P., Diaz, J., Dysager, L., Hall, W., Kerkmeijer, L., Lawton, C.A., Murray, J., Nyborg, C.J., Pos, F.J., Rigo, M., Schytte, T., Sidhom, M., Sohaib, A., Tan, A., van der Voort van Zyp, J., Vesprini, D., Zelefsky, M.J., Tree, A.

Volltext